布托啡诺联合瑞芬太尼用于子宫肌瘤栓塞术患者自控镇痛效果观察  

Patient-controlled Interavenous Analgesia with Butorphanol Combined with Remifentanil in Patients with Uterine Fibroids Embolization

作　　者：叶欲锋 

机构地区：[1]义乌市北苑街道社区卫生服务中心麻醉科,浙江义乌322000

出　　处：《中国药师》2015年第12期2090-2091,共2页China Pharmacist

摘　　要：目的:观察布托啡诺联合瑞芬太尼用于子宫肌瘤栓塞术患者自控镇痛的效果。方法:子宫肌瘤栓塞术患者68例按入院先后顺序分为观察组(n=35)和对照组(n=33),择期行子宫肌瘤栓塞术。对照组予芬太尼自控镇痛舰察组予布托啡诺联合瑞芬太尼自控镇痛双察两组患者的视觉模拟评分(VAS)、镇静评分、术后疼痛以及药品不良反应等。结果:术后1,4,12,24h,观察组患者的VAS评分、镇静评分均明显低于对照组(P<0.05);观察组术后0级疼痛率达74.3%,明显高于对照组的48.5%(P<0.05);又见察组药品不良反应发生率明显低于对照组(P<0.05)。结论:子宫肌瘤栓塞术后使用布托啡诺和瑞芬太尼联合自控镇痛,可有效减轻患者术后疼痛不良反应少安全可靠值得临床推广使用。Objective： To investigate the patient-controlled intravenous analgesia effect of butorphanol combined with remifentanil in uterine artery embolization for uterine myoma. Methods： Totally 68 cases of uterine fibroids patients were divided into the observa- tion group （ n = 35 ） and the control group （ n = 33 ） according to the admission order, and with time selecting operation. The control group was given fentanyl for patient-controlled intravenous analgesia, while the observation group was treated with butorphanol com- bined with remifeatanil. VAS （visual analog scale）, sedation, postoperative pain and adverse reactions in the two groups were ob- served and compared. Results： VAS and sedation score of the observation group were significantly lower than those of the control groups in 1,4, 12 and 24 h after the operation （P 〈0.05）. Grade 0 pain rate was 74.3% in the observation group after the operation, which was significantly higher than that in the control group （48.5 %, P 〈 0.05 ）. The incidence of adverse drug reactions in the observation group was significantly lower than that in the control group （ P 〈 0.05 ）. Conclusion： The combination of butorphanol and remifentanil in uterine fibroid embolization can effectively reduce postoperative pain and significantly decrease the incidence of adverse reactions with promising safety and reliability, which is worthy of promotion in clinical use.

关 键 词：子宫肌瘤栓塞术 布托啡诺 瑞芬太尼 自控镇痛 

分 类 号：R614[医药卫生—麻醉学] R971.2[医药卫生—外科学]